DOXY4STICARE - doxycycline for sexually transmitted infections; a comprehensive assessment of antimicrobial resistance and engagement - sexually transmitted infections (STIS) represent a significant…
Active Project Grant Awarded Last action
- Award ID
- R01AI192204
- Recipient
-
The Trustees Of Columbia University In The City Of New York UEI QHF5ZZ114M72
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,661,248
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 26% complete
- Place of performance
- New York, NY 10032, USA
Award details come from USAspending.gov.
Description
DOXY4STICARE - doxycycline for sexually transmitted infections; a comprehensive assessment of antimicrobial resistance and engagement - sexually transmitted infections (STIS) represent a significant public health challenge, with increasing prevalence worldwide. Disproportionately affecting young individuals, GAY and bisexual men who have SEX with men (MSM), persons with HIV or on HIV prevention medications, and racial and ethnic minorities, effective prevention strategies are essential. Doxycycline post-exposure prophylaxis (DOXY-PEP) has been shown to reduce bacterial STIS; however, knowledge gaps remain, and there are concerns about engagement, effective use, and the potential antimicrobial resistance consequences. This study proposes a threefold approach to address these questions. (1) create a prospective cohort of 500 participants (300 DOXY-PEP users, 200 eligible non-users as a comparator group) to examine baseline and longitudinal factors mapped to the information-motivation-behavioral skills theoretical framework and identify factors associated with DOXY-PEP care engagement and effective use. (2) collect biological samples from the prospective cohort to evaluate the impact of antimicrobial resistance in persons taking DOXY-PEP using laboratory methods including culture and resistance testing and metagenomics. (3) collect biological samples from up to 100 sexual partners of the cohort to assess the potential for transmission of bacteria between sexual partners using comparative genomics. By addressing these aims, the study will provide valuable insights into the risks, benefits, implementation, and impact of DOXY-PEP, informing future strategies to optimize engagement and maximize STI incidence reduction while minimizing antimicrobial resistance risks.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $823,785 | |
| Original award | $837,463 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| New York Medical College | $23,103 | |
| New York Medical College | $23,103 |
Quick answers
Who received award R01AI192204?
R01AI192204 was awarded to The Trustees Of Columbia University In The City Of New York by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 4, 2025.
How much is award R01AI192204 worth?
$1,661,248 has been obligated on R01AI192204.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award